Journal of Virology & Antiviral ResearchISSN: 2324-8955

IL28B is An Irrelevant Prognostic Factor for HCV in the Era of Highly Effective DAAs

Direct-acting antivirals (DAAs) therapies have ushered in the beginning of new era for HCV treatment. Comparative studies to understand the efficacy, safety and factors associated with treatment non-response to DAAs therapies are much-needed. The present study was conducted primarily to evaluate the efficacy and safety of sofosbuvir based DDAs therapy and secondly to investigate the role of host and viral factors especially rs12979860 with treatment response. This study showed that sofosbuvir based therapy was safe and associated with high rates of sustained virological response in both treatment naive and experienced patients. IL28B rs12979860 was not associated with sofosbuvir based treatment hence an irrelevant prognostic factor in our population.

Special Features

Full Text

View

Track Your Manuscript

Recommended Conferences

Share This Page

Media Partners

Associations